This ongoing effort will assist with the validation of KV4 channelosome as therapeutic targets, and the search for better and effective drug candidates for the treatment of neurodegenerative and cardiovascular diseases in which they are involved. The gene discussed is KCNC1; the disease is cardiovascular disorder.